Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083879 | 0.86 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL19075640 | 0.85 | SCN9A (0.42) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL19075588 | 0.81 | CYP2C19 (0.39) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL22809557 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL17428846 | 0.80 | SSTR4 (0.45) | CYP1A2CYP3A4CYP2C19SMN1; SMN2KMT2A | |
| SCHEMBL22809604 | 0.79 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL10331371 | 0.78 | CYP2C19 (0.44) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL15599157 | 0.77 | SMN1; SMN2 (0.39) | CYP1A2CYP3A4CYP2C19SMN1; SMN2KMT2A | |
| SCHEMBL19075622 | 0.77 | SCN9A (0.43) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19430888 | 0.77 | LMNA (0.41) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203572-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP1A2 330/4885CYP3A4 594/4885CYP2C19 565/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CYP1A2 330/4885CYP3A4 594/4885CYP2C19 565/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP1A2 330/4885CYP3A4 594/4885CYP2C19 565/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CYP1A2 330/4885CYP3A4 594/4885CYP2C19 565/4885 |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | CYP1A2 69/4885CYP3A4 149/4885CYP2C19 179/4885 |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, RRM1 | CYP1A2 69/4885CYP3A4 149/4885CYP2C19 179/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP1A2 330/4885CYP3A4 594/4885CYP2C19 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.